About Zymetas

A proven pioneer and partner to the diagnostics industry

Zymetas is an CDMO-driven company constantly developing new technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care.

Our teams located in China focus on delivering products with the highest quality standards to our customers and partners.  We value partnerships with other leading companies in the industry, sharing knowledge, capabilities, and critical materials in order to supply, develop or manufacture diagnostic solutions on a wide variety of platforms. Through this business model, we ensure that the potentially life-changing diagnostic markers meet the largest global need in the shortest possible time.

Heritage of innovation

Zymetas started in Shanghai in 2020.  It developed the first SARS-CoV-2 diagnostics kit, the gold standard for Coronavirus disease (COVID-19) testing, in 2020. Since then, we have built a strong tradition of innovating, developing, manufacturing and marketing high-quality in vitro diagnostics testing solutions worldwide. Over the years, the cooperation of the Center for Disease Control and Prevention & the Entry-Exit Inspection and Quarantine Bureau of Customs have further bolstered our capabilities and expertise in various clinical areas. Today, working closely with one of the world’s top commercial laboratories, Zymetas combines expertise and experience for the diagnostics market that is more potent than ever.

Pioneers of IVD solutions

Key milestones in our journey include the development of the world’s first fully lyophilized real time PCR assay – better known as LyoBead – which is used around the world today. Our product lines span the range from specialized manual testing and will develop automated testing to fully automated routine testing solutions. In addition, we provide gold standard assays in the fields of infectious disease, vaginal microbiome, and antimicrobial resistance, continuing to offer both novel and routine biomarkers for a variety of other diseases including infection with SARS-CoV-2.

Flexible and reliable business partner

Our CDMO teams located in China are committed to develop and manufacture products with the highest quality. This has earned us a strong reputation among our customers and global partners at leading diagnostic companies. Above all, the insights and know-how that our teams bring to each stage of development of a new biomarker or system keep our customers and partners at the forefront of early diagnostics and state-of-the-art healthcare solutions.